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a  b  s  t  r  a  c  t
Vaccine-mediated  prevention  of primary  HIV-1  infection  at the  heterosexual  mucosal  portal  of  entry  may
be  facilitated  by  highly  optimised  formulations  or  drug  delivery  devices  for  intravaginal  (i.vag)  immuniza-
tion.  Previously  we  described  hydroxyethylcellulose  (HEC)-based  rheologically  structured  gel  vehicles
(RSVs)  for  vaginal  immunization  of  an  HIV-1  vaccine  candidate,  a soluble  recombinant  trimeric  HIV-1
clade-C  envelope  glycoprotein  designated  CN54gp140.  Here  we  investigated  the  efﬁcacy  of lyophilized
solid  dosage  formulations  (LSDFs)  for  prolonging  antigen  stability  and  as  i.vag  delivery  modalities.  LSDFs
were  designed  and  developed  that  upon  i.vag  administration  they  would  reconstitute  with  the  imbibing  of
vaginal  ﬂuid  to  mucoadhesive,  site-retentive  semi-solids.  Mice  were  immunized  with  lyophilized  equiv-
alents  of  (i)  RSVs,  (ii)  modiﬁed  versions  of  the RSVs  more  suited  to  lyophilization  (sodium  carboxymethyl
cellulose  (NaCMC)-based  gels)  and  (iii)  Carbopol® gel,  all  containing  CN54gp140.  NaCMC-based  LSDFs
provided  signiﬁcantly  enhanced  antigen  stability  compared  to  aqueous-based  RSVs.  Rheological  analysis
indicated  the NaCMC-based  LSDFs  would  offer enhanced  vaginal  retention  in  woman  compared  to more
conventional  vaginal  gel  formulations.  All  LSDFs  were  well  tolerated  in  the  mouse  model.  Following  i.vag
administration,  all LSDFs  boosted  systemic  CN54gp140-speciﬁc  antibody  responses  in  sub-cutaneously
primed  mice.  Induction  of  CN54gp140-speciﬁc  antibody  responses  in  the  female  genital  tract  was evi-
®dent.  Of  all  the  LSDFs  the  fastest  releasing  which  was  lyophilized  Carbopol gel  elicited  immune  responses
comparable  to buffer  instillation  of antigen  suggesting  that  rather  than  slower  sustained  release,  initial
high  burst  release  from  the  LSDFs  may  sufﬁce.  The  boosting  of  speciﬁc  immune  responses  upon  i.vag
administration  indicates  that  LSDFs  are  viable  mucosal  vaccine  delivery  modalities  promoting  antigen
stability  and  facilitating  intimate  exposure  of  CN54gp140  to the  mucosal-associated  lymphoid  tissue  of
the  female  genital  tract.. IntroductionThe HIV epidemic is fuelled predominantly by heterosexual
ransmission, notably so in sub-Saharan Africa where women  are
Abbreviations: DSC, differential scanning calorimetry; GNA, Galanthus
ivalis;  HEC, hydroxyethylcellulose; HPMC, hydroxypropylmethylcellulose; LSDFs,
yophilized solid dosage formulations; NaCMC, sodium carboxymethyl cellulose; PC,
olycarbophil; PVP, polyvinylpyrollidone; RSVs, rheologically structured gel vehi-
les; SVF, simulated vaginal ﬂuid.
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disproportionately infected particularly in the 15–24-year-old age
range [1]. The exact mechanisms whereby HIV infects across the
vaginal mucosal barrier are not fully elucidated [2], although stud-
ies with SIV indicate that HIV rapidly disseminates once across
the vaginal epithelium [3]. As such, there is profound scientiﬁc
rationale to pursue the development of female-controlled preven-
tive strategies, principally involving the cervico-vaginal region,
the predominant mucosal viral portal of entry in heterosexual
transmission. To be fully effective, such a vaccine should provide
sterilising immunity in the vaginal mucosal environment by induc-
Open access under CC BY license.ing sustained robust protective immune effector function against
diverse viral isolates.
How  to achieve sustained immune effector function, particu-
larly humoral immune effector function by way  of neutralising
cine 2
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ntibody or rapid effective recall of immunological memory at
ucosal surfaces is the subject of intense investigation. In addition,
rom a formulation/drug delivery perspective to ensure equity of
ccess, particularly in the context of sub-Saharan Africa, such a vac-
ine should preferentially be inexpensive, safe, thermo-stable not
equiring cold-chain storage and would facilitate female-controlled
dministration.
It is thought that the envelope spike is the only HIV-1 target
vailable for neutralising antibodies [4]. As a result much emphasis
as been placed on viral surface envelope glycoproteins as HIV-
 vaccine candidates. The efﬁcacy of protein pharmaceuticals as
accines depends upon maintaining storage stability as well as
ntended antigenicity following administration. Vaginally admin-
stered solubilised protein antigens are subject to leakage at the
dministration site, rapid enzymatic degradation, the inﬂuences of
he menstrual cycle and inadequate exposure to the mucosal asso-
iated lymphoid tissue. There are a limited number of reports of
aginal immunization in women [5–11] and, with the exception of
hree studies [5–7] they have employed a known potent mucosal
mmunogen-cholera toxin subunit B that does not require the use
f an adjuvant.
We  previously reported on the design and development of
ell-tolerated mucoadhesive, syringeable, rheologically structured
emi-solid vehicles (RSVs) for site-retentive vaginal administra-
ion of an HIV-1 vaccine candidate – a recombinant clade-C gp140
nvelope protein (CN54gp140), in the rabbit model [12,13]. While
he RSVs were a viable delivery modality for vaginal immuniza-
ion as determined by the elicitation of vaccine-speciﬁc serum
mmunoglobulin (Ig) G, and vaccine-speciﬁc IgG and IgA in genital
ract secretions, the vaccine was not stable within the aqueous-
ased preserved RSV formulations. The antigenicity of CN54gp140
ltered over the course of prolonged storage and this was  more
ronounced the higher the storage temperature. In a related study,
epeated vaginal exposure of CN54gp140, formulated within a
arbopol® semi-solid, was well tolerated and induced systemic and
ucosal IgG antibody responses in the rabbit model [14].
Herein  we report the formulation and vaginal delivery of
N54gp140 within solid dosage forms; lyophilized equivalents of
he Carbopol®, RSV and modiﬁed RSV semi-solid formulations. The
nnovative, robust, lyophilized solid dosage formulations (LSDFs)
n this study were more conducive to CN54gp140 stability with
he potential to offer improved patient acceptability for vaginal
dministration than the equivalent semi-solid formulations. In
ddition, the viability of the LSDFs as delivery modalities for vagi-
al immunization was demonstrated by the ability of the vaginally
dministered lyophilized formulations containing CN54gp140 to
oost subcutaneously primed mice.
. Materials and methods
.1.  Materials
Polyvinylpyrollidone (PVP) (Plasdone® K-90, Mv 1.3 M)  and
olycarbophil (PC) (Noveon® AA1, divinyl crosslinked polyacrylic
cid) were kindly donated by International Speciality Products
Ohio, USA) and Noveon Pharma GmbH & Co KG (Raubling,
ermany), respectively. HEC (Natrosol 250 HHX and 250 G)
nd sodium NaCMC (Blanose® 7LF, 7MF, and 7HF) were also
indly donated by Aqualon (Warrington, UK). GMP  manufactured
arbopol® 974P gel, formulation #2449 was kindly donated by
article Sciences (Bethlehem, PA, USA). Galanthus nivalis (GNA)
as obtained from Vector Laboratories (Peterborough, England).
,3′,5,5′-Tetramethylbenzidine peroxidase substrate (TMB/E) was
btained from Cygnus Technologies Inc. (North Carolina, USA).
N54gp140 (gp120 plus the ectodomain of gp41) was  encoded by9 (2011) 4512– 4520 4513
the CN54gp140REKE HIV-1 envelope gene cassette derived from
the clade-C/B′ HIV-1 molecular clone p97CN54 of Chinese ori-
gin developed by Wolf and Wagner, University of Regensburg,
Germany [15,16]. CN54gp140 was  produced as a recombinant
product in CHO cells by S. Jeffs, Imperial College, London, and
manufactured to GMP  speciﬁcation by Polymun Scientiﬁc (Vienna,
Austria) who  also donated the HIV-1 gp41 speciﬁc monoclonal
antibody 5F3 (HuMab 5F3). Sodium hydroxide, phosphate buffered
saline containing Tween 20 (PBS-T), sterile-ﬁltered porcine serum
and goat anti-human horseradish peroxidase (HRP)-conjugated IgG
were purchased from Sigma–Aldrich (Poole, Dorset, UK). Goat anti-
mouse HRP-conjugated IgA and biotinylated goat anti-mouse IgA
were obtained from AbD Serotec (UK). HRP-conjugated strepta-
vidin was  purchased from R&D Systems (MN, USA). 25X protease
inhibitor cocktail was  obtained from Roche (Hertfordshire, UK).
Reactibind 96 well microplates were obtained from Perbio Science
(Northumberland, England). Nunc Maxisorp 96 well microplates
were obtained from Nalge Nunc International (Rochester, NY).
Nalgene tubing (PVC, 3 mm internal diameter, 5 mm outer diam-
eter, 1 mm Wall) was  purchased from VWR  International Ltd.
(Dublin, Ireland) and blister packs were kindly supplied by Almac
(Craigavon, UK) and Warner Chilcott (Larne, UK). Ultra-pure water
was  obtained using an Elga Purelab Maxima system. Six to 8-week
old female BALB/c mice were obtained from Harlan Ltd., UK. All
in vivo procedures were carried out in compliance with the United
Kingdom Animal (Scientiﬁc Procedures) Act 1986 and associated
Codes of Practice for the Housing and Care of Animals.
2.2. Preparation of semi-solids
2.2.1.  Hydroxyethylcellulose (HEC) based semi-solids
Preparation of the HEC based RSV formulations has been
described previously [13]. Brieﬂy, a HiVac® Bowl (Summit Medical
Ltd., Gloucestershire, UK) was used to facilitate mixing under vac-
uum following the stepwise addition of components. Poylcarbophil
(PC) (3% w/w) was  ﬁrst added to the bowl containing deionised
water and sodium hydroxide prior to the addition of HEC (3 or 5%
w/w)  followed by polyvinylpyrollidone (PVP) (4% w/w).
2.2.2.  Sodium carboxymethyl cellulose (NaCMC) based
semi-solids
PC  (3% w/w) was  added to the vortex produced in a metal beaker
by rapid stirring (at 500 rev min−1) of deionised water and the
required amount of NaOH to reach pH 6 using a Heidolph mechan-
ical stirrer. Following complete dissolution of the mucoadhesive
component, NaCMC (3, 5 or 10% w/w) and PVP (4% w/w) were
added stepwise following attainment of homogeneity. The gels
were transferred to sterile centrifuge tubes, gently centrifuged and
stored for 24 h (ambient temperature) prior to analysis.
2.3. Flow analysis of semi-solids pre-lyophilization under
continuous shear
Flow  rheometry was conducted using an AR2000 rheometer
(T.A. Instruments, Surrey, England) at 25 ± 0.1 ◦C using a 6 cm diam-
eter parallel plate geometry (selected according to formulation
consistency) and a gap of 1000 m,  as previously reported [12].
Flow curves (plots of viscosity versus shear rate) were examined in
the range of 0.1–100 s−1.
2.4. Preparation of CN54gp140 loaded semi-solids2.4.1. For lyophilized solid dosage tablet formation
NaCMC semi-solid (2.8 g) was  weighed into a 5 ml  syringe bar-
rel. The semi-solid loaded syringe barrel was attached to a second
syringe via a 1.5 cm length of Nalgene tubing. CN54gp140 (200 l
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t 530 g/ml) was added to the semi-solid containing syringe bar-
el via pipette and the plunger replaced. Uniform distribution of
N54gp140 throughout the semi-solid formulation was achieved
y carrying out 40 passes of the syringe barrel contents from one
yringe to the other (method previously validated [13]).
.4.2.  For lyophilized solid dosage rod formation for mouse
mmunization studies
Semi-solids  (HEC- and NaCMC-based) (0.36 g) were weighed
nto a speed mixing pot prior to the addition of CN54gp140 (180 l
t 3.5 mg/ml). 2 Spin cycles at 3300 rpm for 30 s were carried out
o provide uniform antigen distribution throughout the semi-solid
ormulations. The same lyophilization protocol was adopted for
ach formulation.
.5.  Differential scanning calorimetry (DSC) of semi-solids
re-lyophilization
To  optimise the lyophilization protocols, the glass transition
emperatures of the selected and cooled semi-solid formulations
ere investigated by DSC using hermetic pans (DSC Q100, TA
nstruments, Surrey, UK). Following cooling to −60 ◦C and holding
sothermally for 5 min, the samples were heated at 2–40 ◦C using a
odulated procedure (±0.4 ◦C every 0.5 s).
.6.  Lyophilization
Prior to lyophilization, semi-solid formulations were dispensed
nto suitable blister packs using a TS250 Digital Timed Dispenser
Adhesive Dispensing Ltd., Buckinghamshire, UK) for tablet forma-
ion or alternatively extruded into nalgene tubing with the use of a
 ml  syringe for rod formation. Lyophilization was carried out using
he Advantage Freeze Dryer (VirTis, Gardiner, NY, USA). Blister
acks/tubing were placed on the shelf and a 4 h thermal treatment
tep was carried out at −28 ◦C. This temperature was maintained for
 further 2 h while the chamber pressure was reduced to 100 mTorr.
rimary drying commenced with a 4 h hold under these conditions
ollowed by a 1 h ramp to and 2 h hold at −20 ◦C. The temperature
as further ramped to 0 ◦C over 2 h then held for 2 h at 500 mTorr
ollowed by a 2 h ramp to 20 ◦C. Secondary drying was  then per-
ormed at 27 ◦C for 4 h at a reduced pressure of 50 mTorr. Following
yophilization samples were transferred into individual sterile uni-
ersal tubes.
.7.  Friability studies
Each  lyophilized solid dosage tablet formulation tested (n = 5)
as weighed and transferred into the test drum of a Copley Sci-
ntiﬁc friability tester (25 rpm, 4 min), during which they are
ubjected to the rolling movement around the drum which has
 curved aperture allowing the formulations to rise and then fall
ver a distance of ∼16 cm.  The dosage forms were then expelled,
eweighed and any decrease in weight recorded.
.8. In vitro dilution of lyophilized solid dosage tablet
ormulations in simulated vaginal ﬂuid (SVF)
SVF was prepared as previously described [17]. NaCl (3.51 g),
OH (1.40 g), Ca(OH)2 (0.222 g), bovine serum albumin (BSA)
0.018 g), lactic acid (2 g), acetic acid (1 g), glycerol (0.16 g), urea
0.4 g) and glucose (5 g) were dissolved in 1 L of deionised water,
ollowed by adjustment to pH 4.2 with HCl. Solid dosage tablet
ormulations were diluted and thoroughly mixed with a deﬁned
olume of SVF (1 ml)  and the dynamic rheological properties
nalyzed. Oscillatory rheometry was conducted within the linear
iscoelastic region over a frequency range from 0.1 to 10 Hz as9 (2011) 4512– 4520
described  elsewhere [12]. The dilution ratio was  chosen on the basis
of that normally encountered in the vagina following insertion of
the delivery vehicle [17].
2.9.  ELISA for the quantiﬁcation of CN54gp140
A heterogeneous indirect sandwich ELISA was optimised
for quantiﬁcation of CN54gp140 in PBST (linear concentration
range 0.003–0.05 g/ml, R2 > 0.999). Wells were incubated with
50 l/well of GNA at 10 g/ml in deionised water (5 h at 37 ◦C). The
wells were washed (5× 300 l PBS-T) and blocked for 1 h at 37 ◦C
with PBST containing 5% porcine serum (PBS-T-serum). Standards,
samples and controls were prepared in PBS-T (n = 4), and incubated
overnight at ambient temperature. The wells were washed and
incubated with 50 l/well HuMab 5F3 (1 g/ml in PBS-T-serum)
for 2 h at 37 ◦C. Following washing, bound antibody was  detected
using 50 l/well goat anti-human IgG peroxidase conjugate diluted
1:5 K in PBS-T-serum and incubated for 1 h at 37 ◦C. After washing,
the wells were incubated with 100 l TMB/E for 5 min. The reaction
was terminated by the addition of 50 l of 2.5 M H2SO4. Plates were
read immediately at A450.
2.10. In vitro release of CN54gp140 from lyophilized solid dosage
tablet  or rod formulations
Each  CN54gp140 containing lyophilized tablet (n = 4) was placed
in a sterile polypropylene pot containing release media (PBS-T,
30 ml)  prior to housing in an orbital incubated shaker (Sanyo Gal-
lenkamp, 100 rpm) maintained at 37 ◦C. At predetermined time
intervals the release medium was  sampled (3 ml)  and replaced with
fresh pre-warmed dissolution media. Samples were diluted in PBS-
T for concentration analysis by ELISA. For rods dissolution volume
was 20 ml  and sample volume was  2 ml.  Dissolution volumes were
selected to maintain sink conditions.
2.11. CN54gp140 stability assessment within lyophilized solid
dosage  tablet formulations
Stability  assessment was carried out in a similar fashion to the
described release protocol. Following complete dissolution of the
CN54gp140 containing lyophilized solid dosage tablets in PBS-T
(30 ml)  a sample was taken and diluted in PBS-T for concentration
analysis by ELISA.
2.12.  Mouse immunogenicity study
Animals were assigned to experimental groups where n = 5
(Table 1). Mice received a subcutaneous (s.c.) prime (Day 0) then
an intra-vaginal (i.vag.) boost three times at 21-day intervals (Days
21, 42, 63) with vaginally administered rod formulations (Table 1).
Mice were lightly anesthetised and the rod formulations were
inserted into the vagina using a positive displacement pipette
(Gilson Microman – 100 l maximum volume) and a tip with the
end cut off and ﬁled down to smoothness. To thin the vaginal
epithelium and improve protein uptake, mice were treated subcu-
taneously with 2 mg  of depoprovera (in 50 l PBS) 5 days prior to
the ﬁrst and third vaginal immunization. Blood samples were taken
from the tail vein of mice on Days 20, 41, 62, and 83 and by cardiac
puncture on Day 120. Blood samples were centrifuged following
clotting for collection of sera. Vaginal lavages were conducted on
Day 83. Vaginal lavages were collected and pooled by ﬂushing the
vaginal lumen three times with a 25 l volume of PBS using a pos-
itive displacement pipette. 5 l of 25X protease inhibitor cocktail
was added to the vaginal eluates, which were incubated on ice for
L. Donnelly et al. / Vaccine 29 (2011) 4512– 4520 4515
Table  1
Assignment of animals to experimental groups.
Experimental group s.c. Prime Day 0 i.vag boost (Day 21, 42, 63)
A 50 l PBS 50 l PBS
B 10  g CN54gp140 in
50 l PBS
10 g CN54gp140 in 50 l
PBS
C  10 g CN54gp140 in
50 l PBS
10 g CN54gp140 in a
lyophilized equivalent of
PC3HEC250HHX5PVP4 (5%
HEC-based RSV) semi-solid
(13)
D 10  g CN54gp140 in
50 l PBS
10 g CN54gp140 in a
lyophilized equivalent of
PC3Blanose7LF3PVP4
semi-solid
E 10 g CN54gp140 in
50 l PBS
10 g CN54gp140 in a
lyophilized equivalent of
Carbopol® semi-solid
A group receiving a single s.c. injection of CN54gp140 was omitted as previous
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Fig. 1. Mean log viscosity versus log shear rate (n = 4) of semi-solid formula-
tions  at 25 ◦C prepared from [a] () PC3HEC250G1, (©) PC3HEC250HHX1, (+)xperiments  have indicated this results in negligible titres (unpublished data).
0 min  prior to centrifugation to remove the mucus/cellular pellet.
ll samples were stored at −80 ◦C until analysis.
.13. CN54gp140-speciﬁc antibody ELISAs
Binding antibodies against CN54gp140 in vaginal lavage and
erum samples were measured a quantitative ELISA. 96-Well plates
ere coated with CN54gp140 and blocked with 1% BSA as before.
gG or IgA standards were used on each plate to quantify the
N54gp140 speciﬁc antibodies. Experimental samples were diluted
:100, 1:1000 and 1:10,000 (sera) or 1:10 and 1:50 (lavage) to
nsure the absorbance reading measured fell within the linear
ange of the standard curve. Bound IgG was detected by incubation
or 1 h at 37 ◦C with HRP-conjugated goat anti-mouse IgG, bound
gA was detected using biotinylated anti-mouse IgA and followed
y Streptavidin-HRP. Plates were washed and developed with 50 l
MB/E substrate and the reaction was terminated by the addition
f 50 l of 2 M H2SO4 and read at A450. Vaginal lavage values were
ormalised against the total IgA or IgG measured in the same sam-
le.
. Results
.1. Preparation of semi-solids
Semi-solids  (Table 2) were prepared using either an overhead
tirrer or HiVac® bowl, the choice of which was dependent upon
he viscosity of the systems being prepared. The lower viscosity of
he NaCMC-based semi-solids permitted use of the overhead stirrer
nd although some degree of aeration occurred this was readily
emoved upon gentle centrifugation (min). It had previously been
etermined that overhead stirring was not suitable for preparation
f the HEC-based semi-solids due to the high rate of shear required
o achieve uniform mixing, excessive aeration and the potential
or high shearing stresses to trigger mechanical breakdown of the
olymeric components. To overcome this, mixing was  carried out
nder vacuum with the use of the HiVac® mixing bowl.
.2.  Flow analysis of semi-solids pre-lyophilization under
ontinuous shearFollowing  dispensing trials a number of semi-solid formulations
ere selected for rheological ﬂow analysis. The inﬂuence of shear
ate on the shear viscosity of the selected HEC- and NaCMC-based
emi-solids is shown in Fig. 1a and b, respectively. Flow analysisPC3HEC205HHX5,  () PC3HEC250HHX1PVP4, and [b] () PC3Blanose7LF10PVP4,
()  PC3Blanose7LF5PVP4, (♦) PC3Blanose7LF3PVP4. Standard error bars have been
omitted  for clarity – coefﬁcient of error<5% throughout.
showed that all the semi-solid formulations were pseudoplastic
in nature in that they displayed decreasing shear viscosity with
increasing shear rate. The power law function was  used to deter-
mine ﬂow consistency () of the materials understudy (at 1 s−1)
(Table 2).
3.3.  DSC analysis of semi-solids pre-lyophilization
On the basis of rheological analysis and dispensing trials, deter-
mined by viscosity and ability to settle into blister pack wells,
formulations containing Blanose 7LF were chosen for lyophiliza-
tion. For all semi-solid formulations in the absence and presence
of CN54gp140, the glass transition temperature was identiﬁed
between −21 and −22 ◦C.
3.4.  Lyophilization
Three solid dosage forms with different dimensions were
prepared (Fig. 2a–c). LSDFs containing 10% Blanose 7LF were
inconsistent in structure whereas those containing lower levels of
Blanose 7LF provided uniform units suitable for further investiga-
tion.
3.5. Friability studies
Following  friability testing no lyophilized solid dosage formu-
lation tested (both those shown in Fig. 2a and b) was subject to
fracture or exterior damage. No loss of weight occurred whereas
slight increases in weight were detected (<8%).
3.6. SVF dilution studiesFollowing  reconstitution of the LSDFs designed for i.vag
administration (Fig. 2a) in SVF (1 tablet per 1 ml) oscillatory
(dynamic) analysis (a measure of consistency) was performed
4516 L.  Donnelly et al. / Vaccine 29 (2011) 4512– 4520
Table  2
Polymer composition of semi-solid formulations and ﬂow rheological properties.
Concentration of semi-solid components (% w/w) Flow rheology
PC PVP HEC 250 NaCMC: Blanose Viscosity/consistency () (Pa sn) (25 ◦C)
HHX G 7HF 7MF  7LF
3 4 1 857 ± 29
3  1 812 ± 49
3 1 399  ± 14
3 4 5  1210 ± 119
3 4  3 687 ± 15
3  4 5 837 ± 63
3  4 3 439 ± 8
3  4 10 978 ± 40
3 4 5 235 ± 7
3 4 3 121 ± 3
F lids. (
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P
37 ◦C. The percentage recovery of CN54gp140 is shown in Fig. 5.ig. 2. Solid dosage formulations following lyophilization of NaCMC-based semi-so
pplicators, (b) alternative LSDFs using round tablet blister pack wells for dispensing
n the resulting semi-solid structure at 37 ◦C and compared to
he original equivalent semi-solid formulations pre-lyophilization
Table 2).
.7.  In vitro release of CN54gp140 from lyophilized solid dosage
ormulations
The  percentage cumulative release of CN54gp140 from solid
osage formulations (formulation type – Fig.  2b) containing
lanose 7LF at 3, 5 and 10% is shown in Fig. 3. Release proﬁles of
N54gp140 were similar, displaying a continuous release of antigen
ith maximum CN54gp140 detectable (Tmax) in the dissolution
edia after a 7–8 h period (Table 3).
The percentage cumulative release of CN54gp140 from
olid dosage formulations (formulation type – Fig. 2c)
ig. 3. Mean (±1 SD) in vitro percentage cumulative release of CN54gp140
n  = 4) from lyophilized NaCMC-based solid dosage tablet formulations () lyo-
C3Blanose7LF10PVP4, () lyo-PC3Blanose7LF5PVP4, (♦) lyoPC3Blanose7LF3PVP4.a) LSDFs suitably sized for i.vag administration using conventional human vaginal
(c) LSDFs used for murine i.vag administration in the mouse immunogenicity study.
lyo-PC3HEC250HHX5PVP4, lyo-PC3Blanose7LF3PVP4 and lyo-
Carbopol® going forward to the mouse immunogenicity study are
shown in Fig. 4.
3.8.  CN54gp140 stability assessment within lyophilized solid
dosage  tablet formulations
Stability  of CN54gp140 within the lyophilized solid
dosage tablet formulation (Formulation type – Fig. 2b) lyo-
PC3Blanose7LF3PVP4 was assessed following prolonged storage atNo loss in recoverable CN54gp140 (>70%) was experienced over
the duration of the study.
Fig. 4. Mean (±1 SD) in vitro percentage cumulative release of CN54gp140 (n = 4)
from lyophilized rods (formulation type – Fig. 2c) going forward to the mouse
immunogenicity  study (©) lyo-Carbopol® , () lyo-PC3Blanose7LF3PVP4 and ()
lyo-PC3HEC250HHX5PVP4.
L. Donnelly et al. / Vaccine 29 (2011) 4512– 4520 4517
Table  3
Polymer composition of NaCMC-based semi-solids selected for lyophilization, oscillatory rheological properties pre- and post-lyophilization and in vitro release data post-
lyophilization.
Conc. of semi-solid components (%w/w) Oscillatory rheology data: Consistency In vitro release data
(25 ◦C) (37 ◦C) (37 ◦C)
PC PVP NaCMC: Blanose Semi-solid pre-lyophilization Semi-solid pre-lyophilization SVF reconstituted % release
7LF (Pa s) x ± S.D (Pa s) x ± S.D (Pa s) x ± S.D (1 h, 6 h, Tmax)
3 4 10 916 ± 21 689 ± 8 428 ± 16 12.43 ± 0.90 (1 h)
62.51  ± 8.42 (6 h)
Tmax:  78.70 ± 8.91 (8 h)
3 4 5 292 ± 7 227 ± 16 128 ± 4 11.05 ± 1.15 (1 h)
61.97  ± 9.23 (6 h)
Tmax:  84.93 ± 4.3 (7 h)
3 4 3 218 ± 5 186 ± 4 74 ± 13 9.01 ± 2.23 (1 h)
62.31  ± 12.88 (6 h)
Tmax:  68.17 ± 4.38 (8 h)
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Fig. 7. CN54gp140-speciﬁc IgG (a) and IgA (b) responses detected in vaginal lavageig. 5. Mean (±1 SD) recovery of CN54gp140 (n = 4) from lyo-PC3Blanose7LF3PVP4
olid  dosage tablets (formulation type – Fig. 2b) following prolonged storage at 37 ◦C.
.9. Mouse immunogenicity study
All pre-treatment serum samples and those from the control
aïve experimental Group A at every time point tested negative for
N54gp140-speciﬁc IgG and IgA antibody (Fig. 6). With the excep-
ion of one apparent responder in Group D, CN54gp140-speciﬁc
gA responses were neglible. Group B exhibited a signiﬁcantly
nhanced CN54gp140-speciﬁc serum IgG response on Days 41 and
3 against other groups and compared to the naïve control Group A
P < 0.01; Dunnet Multiple Comparisons test). Furthermore, Groups
 and E had signiﬁcant CN54gp140-speciﬁc serum IgG responses
y Day 120, against other groups and compared to the naïve con-
rol Group A (P < 0.01 and P < 0.05, respectively; Dunnet Multiple
omparisons test). Interestingly, Group E maintained CN54gp140-
peciﬁc IgG antibody responses between Days 83 and 120 while
n all other the responding groups the antibody levels had waned
s expected with the ﬁnal vaccination have been given at Day 63
Fig. 6). To determine mucosal immune responses, CN54gp140-
peciﬁc IgG (Fig. 7a) and IgA (Fig. 7b) were quantiﬁed in vaginal
ig. 6. CN54gp140-speciﬁc serum IgG time-course (n = 5). (©) Group A, () Group
,  () Group C, () Group D and () Group E. Error bars omitted for clarity.samples (Day 83). Values are normalised to total IgG or IgA measured in the same
sample.  (©) Group A, () Group B, () Group C, () Group D () and Group E. Error
bars  represent ±1 SD.
lavage. CN54 speciﬁc IgG was  detectable in the vaginal lavage of
immunized mice, IgA was  only detectable in the carbopol group.
4.  Discussion
To the best of our knowledge, this article is the ﬁrst example
of i.vag immunization employing LSDFs derived from semi-solids.
Previously soluble recombinant HIV-1 gp140 has been shown to
be immunogenic in the absence of mucosal adjuvant, upon i.vag
immunization and formulated within semi-solids [13,14]. This is
the ﬁrst demonstration that soluble recombinant HIV-1 gp140
is immunogenic in the absence of mucosal adjuvant, upon i.vag
immunization, and formulated within LSDFs. Moreover, the for-
mulations were well tolerated in the murine model.
In  general, semi-solid dosage forms are currently the most com-
mon dosage form used for i.vag delivery [18]. They have many
desirable attributes that make them suitable for vaginal deliv-
ery but are also associated with messiness and poor retention.
Previously we  developed highly viscous, mucoadhesive gel sys-
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ems, developed for site-retentive application of CN54gp140 to
he vagina [13]. Although the GMP  manufactured CN54gp140 has
roven to be exceptionally stable in simple buffer solutions (D.
atinger – personal communication), stability was severely com-
romised when formulated within the aqueous-based RSVs. So
lthough both the RSVs and a considerably less viscous Carbopol®
emi-solid formulation [13,14] have proven to be viable deliv-
ry modalities for i.vag immunization with CN54gp140, from a
ractical perspective such aqueous-based semi-solid formulations
equiring labour intensive bed-side mixing to overcome instability
oncerns are neither suitable for the clinic or ﬁeld.
Lyophilization is routinely used for the preparation of stable
harmaceutical products. In the present study lyophilization of
emi-solids was explored with the intention of developing LSDFs
or i.vag immunization that were conducive to antigen stability.
esirable attributes of the resulting LSDFs included that they would
rovide rapid stabilisation of antigen, long-term product stability
avoiding cold-chain storage) and ease of reconstitution upon i.vag
dministration. Upon administration these formulations were pre-
icted to reconstitute to semi-solids by the imbibing of vaginal
uid, permitting intimate contact of the vaccine candidate with the
aginal epithelium. Upon reconstitution the formulations would
etain the intended beneﬁcial attributes of the original semi-solid
ormulations, including mucoadhesiveness and in the case of the
yophilized RSVs enhanced viscoelasticity, thus enhanced retention
ompared with more conventional vaginal semi-solid formula-
ions, including Carbopol®.
To enable preparation of the LSDFs, equivalent to their respec-
ive semi-solid formulations but with deﬁned dimensions (suitably
ranslational to the human clinic), semi-solids were dispensed
nto blister packs and subsequently lyophilized. Due to their high
iscosity and resistance to deformation the RSVs described pre-
iously [12,13] were not suitable for dispensing, as they were
esistant to settling within wells. The RSV semi-solid formulation
PC3HEC250HHX5PVP4) [12] underwent modiﬁcation to reduce
iscosity thus facilitating lyophilization in blister packs, deter-
ined visually through dispensing trials and by rheological ﬂow
nalysis (manifested as a reduction in viscosity). Modiﬁcations tri-
lled included a reduction in the HEC250HHX content from 5%
o 1%, omission of the PVP component, and omission of the PVP
omponent plus substitution of the HEC250HHX polymer compo-
ent with HEC250G, a grade exhibiting lower Brookﬁeld viscosity
400 mPa  s compared to 15,000 mPa  s). Rheological ﬂow analysis,
sed as an aid for the optimisation of processing parameters such
s dispensing, in addition to predicting the way in which a material
ill behave upon storage and end-user application, demonstrated
he pseudoplastic nature of all the modiﬁed RSVs. Such shear thin-
ing behaviour was a desirable attribute to facilitate expulsion of
he semi-solids from the dispensing tubes and to ensure adequate
ettling into the blister pack wells. Omission of the PVP component
ad no signiﬁcant effect on consistency (determined using power
aw) whereas reduction of the HEC250HHX content resulted in a
rop in consistency from 3194 ± 177 Pa sn [12]. Substitution with
EC250G in combination with PVP omission also resulted in a drop
n consistency to 399 ± 14 Pa sn. However, dispensing trials demon-
trated that the HEC-based semisolids did not exhibit sufﬁcient
ow properties to settle uniformly into the blister pack wells.
To  overcome this, the HEC component of the original RSV for-
ulations was substituted with NaCMC. NaCMC-based semi-solid
ormulations were subsequently evaluated, and the original RSV
ormulation was  not pursued to lyophilization as uniform dosage
orms suitable for human administration were not attainable. Phar-
aceutical grades of Blanose were investigated with high (7HF),
edium (7MF) and low (7LF) molecular weights (MW).  The Brook-
eld viscosity of Blanose decreases down through the grades –
HF (20,000 mPa  s), 7MF  (600 mPa  s) and 7LF (40 mPa  s). As a result9 (2011) 4512– 4520
when  combined with PVP and PC the consistency of the semi-
solid formulations decreased with decreasing MW of the Blanose
component. The higher viscosity arising from the inclusion of the
7HF grade is likely due to the increased number of physical entan-
glements that the larger molecular weight component may  form,
which in turn may  lead to the increased resistance to deformation
observed in the form of resistance to settling into the blister pack
wells. In contrast to this, inclusion of the 7LF grade resulted in the
formulation of semi-solids that could be adequately dispensed and
subsequently settled into the blister pack wells. As a result the opti-
mised LSDFs described contain Blanose 7LF as part of their overall
polymer component.
To  avoid collapse of the formulations during lyophilization DSC
analysis was conducted to optimise the lyophilization protocols.
Primary drying was maintained below the glass transition tem-
peratures of the semi-solids at −28 ◦C to overcome inefﬁciency of
thermal transfer between the shelf and dispensed semi-solids and
to ensure immobilisation of the polymeric chains thus preserving
structure. Friability testing indicated that the solid-dosage formu-
lations would withstand the rigors of transport and handling. The
slight increases in batch weight were attributed to water uptake
upon re-exposure of the dehydrated formulations to normal atmo-
spheric conditions.
As  anticipated oscillatory analysis conﬁrmed a decrease in con-
sistency of the semi-solid formulations created upon reconstitution
of the LSDFs with SVF compared to the equivalent semi-solids
pre-lyophilization. This was attributed to the lower pH and lower
ratio of solid polymer component to solution of the reconstituted
systems. Although, compared to the original RSV semi-solid formu-
lations the viscosity of the Blanose containing formulations prior to
lyophilization and following reconstitution in SVF was considerably
reduced, the reconstituted formulations (modelling the in vivo sce-
nario) retained consistencies greater than those of commercially
available PC based formulations [12] prior to i.vag administration.
Importantly, based on this observation the LSDFs were anticipated
to offer enhanced vaginal retention compared to more conventional
gels such as Carbopol® which would be subject to further reduc-
tions in viscosity upon i.vag administration due to the imbibing of
vaginal ﬂuid, increases in temperature and exposure to lower pH.
In vitro release of CN54gp140 from the LSDFs containing Blanose
7LF was  sustained over an 8 h period at which point the tablets
had undergone complete dissolution. As anticipated due to changes
in viscosity the LSDFs containing Blanose 7LF release approxi-
mately two-fold faster upon reconstitution (modelling the in vivo
scenario) than the highly viscous RSVs (expulsed into dissolution
medium to model in vivo smearing) [13]. The percentage load-
ing of Blanose 7LF did not inﬂuence in vitro release. As a result
one lyophilized formulation lyo-PC3Blanose7LF3PVP4 was pro-
gressed to stability and immunogenicity analysis. The degree of
matrix associated dampening varies with each formulation type
and over the course of a dissolution study using the speciﬁed
ELISA. Therefore the concentration of CN54gp140 was  determined
against a CN54gp140 in PBS-T calibration curve and matrix asso-
ciated dampening was  not corrected for. As a result recovery of
CN54gp140 as determined by ELISA was  not expected to reach
100%. Importantly antigenicity/recovery was  retained at greater
than 70% for at least 5 months when CN54gp140 was  formulated
within lyo-PC3Blanose7LF3PVP4 indicating that lyophilization sig-
niﬁcantly enhanced long-term stability under accelerated storage
conditions. Comparatively, recovery had dropped in the aqueous-
based RSVs from 77% to 21% by Day 9 at 37 ◦C [13]. PVP, one
of the polymer components of the LSDFs is reported to be
a cryoprotectant [19,20], which may  have been a contributing
factor.
Comparative in vitro release studies were also conducted on the
LSDFs intended for the mouse immunogenicity study (Fig. 2c). The
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ationale for comparing the optimised Blanose 7LF containing LSDF
o lyophilized equivalents of the original RSV and of Carbopol® in
he mouse immunogenicity study was that the selected formu-
ations present three very different rates of release. The RSV and
arbopol® gel can be lyophilized in rod format only. As previously
iscussed the RSV is not suitable for lyophilization within blis-
er pack wells and the lyophilized equivalent of Carbopol® gel is
pongy with inadequate rigidity for i.vag administration. Due to
heir small size the in vitro release proﬁles of the lyophilized rods
ere of limited value and were merely designed to be demon-
trative that due to the nature of the formulation components
hese rods release antigen at varying rates in vitro as was  the
ase with the equivalent formulations of larger size. As anticipated
he lyophilized version of Carbopol® gel (lyo-Carbopol®) exhib-
ted rapid release whereas the lyophilized version of the highly
iscous unmodiﬁed RSV (lyo-PC3HEC250HHX5PVP4) had a much
ore sustained release proﬁle. Comparative release proﬁles of
he larger equivalent formulations designed for non-human pri-
ate (NHP) or human administration present more distinguishable
elease proﬁles further separating the quick release formulations
rom the more sustained release formulations. Inevitably formu-
ation size is largely dictated by the constraints of animal models.
ow inﬂuential this is to enabling adequate comparison of formula-
ions that are designed to release at varying rates in vivo is yet to be
etermined.
HIV envelope proteins are notoriously poorly immunogenic.
ontrary to our previously conducted rabbit experiments [14] prior
xperiments in mice have indicated that i.vag as a sole route of
dministration for CN54gp140 alone does not elicit detectable
mmune responses (unpublished data). As a result we  selected a
eterologous prime-boost regimen, increasingly prevalent in HIV
accine research [21]. Remarkably, all topically administered i.vag
ormulations boosted sub-cutaneously primed mice, importantly in
he absence of adjuvant. Of the responses detected locally within
he vagina we cannot rule out, as has been reported in HIV infec-
ion [22], that serum transudation contributed. Nevertheless, the
SDF inserts have been shown to be a viable delivery modality
or i.vag immunization. With respect to immunogenicity the study
ata indicated that in the case of the mouse model the LSDFs were
ot offering any additional beneﬁts over i.vag administration of
N54gp140 formulated within PBS buffer alone. Perhaps with the
xception of lyophilized Carbopol® that may  be prolonging or aug-
enting CN54gp140-speciﬁc systemic humoral effector immune
esponses. The formulation (lyo-PC3HEC250HHX5PVP4) with the
lowest release induces the lowest response, whereas the formu-
ation (lyo-Carbopol®) with the fastest release closest to the PBS
lone scenario marginally prolongs or augments the response. How
ranslational this may  be to other animal models, in particular NHPs
nd more importantly to humans is yet to be determined but this
ay be indicative that sustained release is not required rather
n initial high burst release may  sufﬁce. The perceived beneﬁts
uch as enhanced retention that drive such formulation develop-
ent with respect to improving immune responses may  not be
holly realised due to the size restrictions of the murine vaginal
umen.
However although the LSDFs did not augment immune
esponses in comparison to those following administration of
ntigen in PBS alone the problems associated with human i.vag
dministration of vaccines in simple buffer solutions are not to
e underestimated. As such the LSDFs that elicited comparable
mmune responses to those of the PBS group have the potential
o provide additional attributes for vaginal mucosal vaccine deliv-
ry in humans. LSDFs can be self-administered with relative ease
sing conventional solid dosage vaginal applicators, compared to
he instillation of buffers and to the administration of semi-solids,
hus promoting higher acceptability and enhanced user compli-
[
[9 (2011) 4512– 4520 4519
ance.  The stability advantages have the potential to eliminate the
requirement for cold-chain storage, and the reduction in weight
associated with the removal of water could reduce constraints on
distribution including expense.
5. Conclusion
This study has described the design and development of LSDFs
derived from the lyophilization of mucoadhesive semi-solid dosage
forms. CN54gp140 was formulated within the LSDFs for i.vag
administration. Upon application the LSDFs boosted s.c. primed
mice indicating that the LSDFs reconsituted in vivo with the imbib-
ing of vaginal ﬂuid, resulting in intimate exposure of CN54gp140
with the mucosal-associated lymphoid tissue of the female genital
tract. The LSDFs were conducive to long-term antigen storage sta-
bility. To the best of our knowledge this is the ﬁrst description of
lyophilized solid dosage forms as vaginal mucosal vaccine delivery
modalities.
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